李氏大藥廠(00950.HK):Teglutik®取得藥品註冊許可證
格隆匯6月21日丨李氏大藥廠(00950.HK)公吿,於2022年5月31日,Teglutik®(利魯唑口服混懸液)已取得中國國家藥品監督管理局的藥品註冊許可證。Teglutik®獲認可用於延長肌萎縮性脊髓側索硬化症("肌萎縮性脊髓側索硬化症")患者的生命或延長其發展至需要機械通氣支持的時間。
肌萎縮性脊髓側索硬化症為罕見疾病,每十萬人出現2至9個病例,發生率為每年每十萬人出現1至3個病例。肌萎縮性脊髓側索硬化症會導致控制隨意肌的運動神經元逐漸喪失。
Teglutik®為Italfarmaco S.A.("Italfarmaco")的引進產品,獲授獨家分銷權,於中國內地、香港、澳門及台灣開發及商業化Teglutik®。
Teglutik®(利魯唑)口服混懸液是用於治療肌萎縮性脊髓側索硬化症的神經保護劑。肌萎縮性脊髓側索硬化症是一種致命、成年發病的神經退行性疾病,影響上及下運動神經元,並與皮質及脊髓運動神經元退化有關。神經退化的體徵及症狀表現為延髓、四肢、胸部及腹部肌肉逐漸無力。20–50%及5–15%的病例分別出現認知功能障礙及痴呆。該疾病是最常見的運動神經元病("運動神經元病")形式之一,佔所有運動神經元病病例的85%以上。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.